ezm
back

Anesthesia

Effective October 2016, the Surgery Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) as noted below. This is a competitive process that will be conducted by the Surgery MISP in 2017. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below.

The following areas are of interest to the Investigator Studies Program Committee:

  • DEVELOP / VALIDATE METHODS TO MEASURE:
    • Intra-operative surgical conditions
    • Postoperative recovery, including but not limited to speed, cost, pain, nausea, vomiting, hypoxemia, neurohumoral response, catabolism, bowel motility, pulmonary or cardiac function, fluid homeostasis, fatigue, sleep disturbance, cerebral function, and surgery-specific quality of recovery/patient satisfaction
    • Perioperative outcomes possibly impacted by intra-operative neuromuscular blockade or peripheral opioid receptor antagonism
  • IMPACT ON INTRA-OPERATIVE SURGICAL CONDITIONS AND PATIENT PATHOPHYSIOLOGY, POSTOPERATIVE RECOVERY, OR PERIOPERATIVE OUTCOMES, IN OVERALL AND/OR IN SPECIAL PATIENT POPULATIONS, OF:
    • Residual neuromuscular block
    • Deep neuromuscular block vs. moderate or no neuromuscular block
    • Duration of neuromuscular block (sustained to end of surgery)
    • Peripheral opioid receptor antagonists
  • USE OF NEUROMUSCULAR BLOCK AND REVERSAL in special patient populations, including but not limited to children, those with burns, in intensive care, ambulatory, or other special settings, those with neuromuscular or psychiatric disorders; or in those undergoing specific surgical procedures that may impact neuromuscular monitoring or management.
  • ENHANCED RECOVERY PROTOCOLS:
    • Impact on speed, cost, quality of recovery from surgery (see 1(b) above), overall and/or in special populations
    • Contribution of neuromuscular relaxant reversal to the impact of a protocol
    • Contribution of peripheral opioid receptor antagonists to the impact of a protocol

    Please complete a full protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the Surgery MISP Committee.

    Critical Activities and Timelines:
    Activity 1st Review Cycle 2nd Review Cycle 3rd Review Cycle 4th Review Cycle 5th Review Cycle
    Full Protocol Submission with Detailed Budget Jan 1, 2017 Mar 1, 2017 May 1, 2017 Jul 3, 2017 Sep 1, 2017
    Final Comments to Investigator Jan 30, 2017 Mar 31, 2017 May 31, 2017 Jul 31, 2017 Sep 29, 2017
    Final Protocol Submission by Investigator Feb 6, 2017 Apr 7, 2017 Jun 7, 2017 Aug 7, 2017 Oct 6, 2017
    Final Protocol Approval by Committee Feb 20, 2017 Apr 21, 2017 Jun 21, 2017 Aug 21, 2017 Oct 20, 2017


    Grant Application


    Contact Information

    Lisa Mount
    Telephone: (267) 305-1258
    E-Mail: lisa_mount@merck.com


    Copyright © Merck & Co. Inc, Kenilworth, NJ USA is known as MSD outside the United States and Canada All rights reserved. | Privacy | Terms of Use
    © Merck & Co. Inc, Kenilworth, NJ USA is known as MSD outside the United States and Canada Privacy | Terms of Use